Evobrutinib的最新3期研究结果使人们对BTK抑制剂治疗多发性硬化症的前景产生了疑问

{"title":"Evobrutinib的最新3期研究结果使人们对BTK抑制剂治疗多发性硬化症的前景产生了疑问","authors":"Susan Fitzgerald","doi":"10.1097/01.nt.0001012040.34944.98","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":19197,"journal":{"name":"Neurology Today","volume":"42 3","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Latest Phase 3 Findings on Evobrutinib Raise Questions About the Future of BTK Inhibitors for Multiple Sclerosis\",\"authors\":\"Susan Fitzgerald\",\"doi\":\"10.1097/01.nt.0001012040.34944.98\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":19197,\"journal\":{\"name\":\"Neurology Today\",\"volume\":\"42 3\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-04-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Neurology Today\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1097/01.nt.0001012040.34944.98\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurology Today","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/01.nt.0001012040.34944.98","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}